Allink raises $42m for bispecific antibody and ADC pipeline
Biotechnology company Allink Biotherapeutics has successfully completed a $42 million Series A financing. The financing round was led by Lanchi Ventures, with participation new investors including Yuanbio Venture Capital, Legend Capital and C&D Emerging Industry Equity Investment, alongside strong support from existing shareholders Gaorong Ventures and Med-Fine… Read More